KYLE MANSCUK: Open Payments
NPI 1104313519 · OCALA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$457 in 22 payments from 13 companies in 2025. Trend: 2023 $996 · 2024 $796 · 2025 $457
Food & beverage: $457
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 6 | $118 |
| EMD Serono, Inc. | 3 | $59 |
| Eisai Inc. | 2 | $49 |
| Gilead Sciences, Inc. | 2 | $35 |
| GENZYME CORPORATION | 1 | $30 |
| TAIHO ONCOLOGY, INC. | 1 | $27 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| Janssen Biotech, Inc. | 1 | $23 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
Products named: Fabhalta, KISQALI, Lenvima, Trodelvy, SARCLISA, LONSURF, ENHERTU, RYBREVANT.
Industry payments across FL — which companies pay providers there.
